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Poster Session I 47CFU-IL3 activity, but lost the capacity to enhance CFU-E. Addi-
tionally, a requirement for IL-9R signaling (IL-9Ra/gc) in BMC
was supported by the absence of Treg CFU-E enhancement of gc
KO marrow. Finally, Treg augmentation of CFU-E in transwell
cultures using B6-wt and B6-Class II-/- Lin- populations showed
that this enhancing activity: a) was not contact dependent and b)
did not require MHC class II expression on the targeted popula-
tions. These findings reveal two distinct pathways of regulation,
i.e. inhibition and enhancement as defined by cytokines, contact de-
pendency and an MHC class II requirement. Current studies have
found neither perforin or fasL are required to mediate either of
these pathways. In total, these results demonstrate for the first
time that Tregs can modulate activity which is critically important
to successful engraftment in clinical BMT, in addition to adaptive
and innate immune responses.122
G-CSF AND FLT3 LIGAND PROMOTE RECOVERY OF HEMATOPOIESIS AF-
TER TOTAL BODY IRRADIATION (TBI) WITHOUT HEMATOPOIETIC STEM
CELL SUPPORT
Georges, G.E.1,2, Pillai, J.N.1, Lesnikov, V.1, Lesnikova, M.1,
Yang, Y.-J.1, Aragon, A.1, Mielcarek, M.1,2 1Fred Hutchinson Cancer
Research Center, Seattle, WA; 2University of Washington, Seattle, WA.
Hematopoietic cells are highly sensitive to radiation damage and
their loss after radiation exposure results in lethal infections. We
asked if intensive supportive care and hematopoietic-specific cyto-
kine treatment after doses of TBI that were previously identified
as lethal would permit survival and promote recovery of endoge-
nous hematopoiesis without requiring hematopoietic stem cell sup-
port in the well-established dog model. Historical results showed
that after 4 Gy TBI and standard supportive care, only 1 of 28
dogs survived with recovery of endogenous hematopoiesis. The
new intensive supportive care regimen for dogs after irradiation in-
cluded an antibiotic use algorithm for empiric treatment of pro-
longed neutropenia and fever and blood transfusion and
intravenous fluid support. Intensive supportive care given to 60
dogs after TBI resulted in significantly improved survival compared
to the historical supportive care.With intensive supportive care, we
observed high rates of survival in dogs following exposure of up to 7
Gy TBI with complete endogenous hematopoietic recovery. Cyto-
kine treatment consisting of granulocyte colony stimulating factor
(G-CSF) alone or combined G-CSF and fms-like tyrosine kinase
3 (flt-3) ligand, (FL) given after TBI did not significantly improve
long term survival compared to recipients of intensive supportive
care alone, but it significantly decreased the duration of intensive,
expensive supportive care. For all cohorts receiving cytokines after
TBI, the recovery of ANC was more rapid compared with support-ANC
Recovery
Platelet
Recovery
TBI
Dose (Gy)
Cytokine
after TBI
Median Days
after TBI
Survival/
Total # of
Dogs Studied
4 no 26 43 4/4
5 no 27 52 3/6
5 G-CSF 20 44 6/6
6 no 33 84 5/6
6 G-CSF 27 64 5/6
6 G-CSF 1 FL 18 53 5/5
7 no 55 77 5/6
7 G-CSF 24 64 5/5
7 G-CSF 1 FL 18 57 6/6
8 no* n/a n/a 0/4
8 G-CSF 1 FL 37 99 1/6
Survival at . day 1120.ive care alone (p\ 0.002). Treatment with the combination of G-
CSF (10 mg/kg/day) and FL (100 mg/kg/day), starting 2 hours after
TBI and continuing until recovery of ANC . 1000/mL resulted in
significantly more rapid recovery of ANC and platelets compared to
G-CSF alone. Follow-up of all surviving dogs .6 months after ir-
radiation showed sustained hematopoiesis and immune reconstitu-
tion. These studies show that in this model, hematopoietic stem
cells survive doses of TBI up to 7 and 8 Gy without requiring infu-
sion of either autologous or allogeneic hematopoietic stem cells,
that intensive supportive care is sufficient to permit reliable survival
after 7 Gy TBI, and that the cytokine combination of G-CSF and
FL is more effective than G-CSF in promoting rapid recovery of
neutrophils and platelets after moderately high dose TBI. The re-
sults are relevant for the treatment of victims of terrorist or acciden-
tal radiation exposure.123
INCREASED EXPANSION, HOMING AND ENGRAFTMENT OF CYTOKINE-
CULTURED CORD BLOOD-DERIVED CD341 CELLS BY TREATMENT
WITH NICOTINAMIDE, A FORM OF VITAMIN B3
Peled, T.1, Adi, S.1, Rosenheimer, N.G.1, Shoham, H.1, Daniely, Y.1,
Nagler, A.2, Rechavi, G.3, Amariglio, N.3, Hirsch, J.J.3, Fibach, E.4,
Peled, A.5 1Gamida Cell Ltd., Jerusalem, Israel; 2Chaim Sheba Medical
Center, Tel-Hashomer, Israel; 3Chaim Sheba Medical Center Tel
Hashomer 52621& Sackler School of Medicine Tel Aviv University,
Tel Aviv, Israel; 4Hadassah - Hebrew University Medical Center, Jeru-
salem, Israel; 5Hadassah - Hebrew University Medical Center, Jerusa-
lem, Israel.
Strategies to expandCD341 cells in vitro and to enhance their re-
populating activity in vivo may improve the clinical outcome of
transplantation. Alas, low engraftment efficacy after ex vivo expan-
sion limits the clinical utility of cultured CD341 cells.
Our study demonstrates that nicotinamide (NAM), a form of vi-
tamin B3 and an inhibitor of ADP ribosylation, attenuates the en-
graftment deficiency of cultured CD341 cells.
Treatment with NAM of cytokine-cultured cord blood (CB) de-
rived CD341 cells significantly increased the proportion of early
(CD38- CD341Lin-) HPC subsets within the expanded CD341
cell population.NAM-treated cultures had 7.5-foldmore SCIDRe-
populating Cells (SRC) than cytokine-alone treated cultures and 9
fold more SRC over the seeded number of SRC. Moreover, an en-
graftment advantage of NAM cultured cells was observed as early as
12 days after transplantation.
A mechanistic probe of NAM cultured cells demonstrated an ini-
tial slower proliferation rate of CD341 cells treated with NAM
than cells exposed to cytokines alone. Treatment with NAM en-
hances CD341 cells migration in response to CXCL12, the ligand
for CXCR4. Furthermore, NAM treatment stimulates significantly
the homing efficacy of cultured CD341 cells to the bone marrow of
NOD/SCID mice. This may explain, at least in part, the increased
engraftment efficacy of cells cultured with cytokines 1 NAM. Ge-
nome wide expression profiles of CD341 cells re-isolated from cy-
tokines and cytokines1NAM cultures demonstrate transcriptional
modulation byNAMof genes implicated in cell migration, motility,
adhesion, protein localization and cell cycle.
Our study unveils a novel activity ofNAMand suggests its clinical
utility in cord blood transplantation.124
MESENCHYMAL STEM CELLS SUPPORT EX VIVO UMBILICAL CORD
BLOOD EXPANSION BY A CONTACT-DEPENDENT ANTI-APOPTOTIC EF-
FECT
Chu, P.1, Huang, J.1, Prasath, A.2, Hwang, W.1 1SingHealth and
Duke-NUS Graduate Medical School, Singapore, Singapore; 2Singapore
General Hospital, Singapore, Singapore.
Aims: Ex vivo expansion of stem and progenitor cells in umbilical
cord blood (UCB) is enhanced by co-culture with mesenchymal
stem cells (MSC). We investigated the mechanism of this
